Topics

Human medicines European public assessment report (EPAR): Prevenar 13, pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Pneumococcal Infections,Immunization, Date of authorisation: 09/12/2009, Revision: 37, Status: Authorised

12:00 EDT 26 Mar 2020 | European Medicines Agency

Human medicines European public assessment report (EPAR): Prevenar 13, pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Pneumococcal Infections,Immunization, Date of authorisation: 09/12/2009, Revision: 37, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Prevenar 13, pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Pneumococcal Infections,Immunization, Date of authorisation: 09/12/2009, Revision: 37, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Prevenar 13, pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Pneumococcal Infections,Immunization, Date of authorisation: 09/12/2009, Revision: 37, Status: Authorised"

Quick Search

Relevant Topics

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...